Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis

References

• MoranA, ZhaoD, GuD, et al. The future impact of population growth and aging on coronary heart disease in China: projections from the coronary heart disease policy model-China. BMC Public Health. 2008;8(1):394. doi:10.1186/1471-2458-8-39419036167
   PubMedGoogle Scholar
• Health and Family Planning Commission of the People’s Republic of China. Graphic: report on nutrition and chronic disease status of Chinese residents; 2015 Available from: http://www.nhc.gov.cn/jkj/s5879/201506/4505528e65f3460fb88685081ff158a2.shtml. Accessed 8 1 2020.
   Google Scholar
• CritchleyJ, LiuJ, ZhaoD, WeiW, CapewellS. Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999. Circulation. 2004;110(10):1236–1244. doi:10.1161/01.CIR.0000140668.91896.AE15337690
   PubMed Web of Science ®Google Scholar
• Joint committee for guideline revision National Expert Committee on Cardiovascular Diseases, National Center for Cardiovascular Diseases Chinese Society of Cardiology, Chinese Medical Association Chinese Diabetes Society, Chinese Medical Association Chinese Society of Endocrinology, Chinese Medical Association Chinese Society of Laboratory Medicine, Chinese Medical Association. Chinese guidelines for the management of dyslipidemia in adults. J Geriatr Cardiol. 2016;2018(15):1–29.
   Google Scholar
• JellingerPS, HandelsmanY, RosenblitPD, et al. American Association of Clinical Endocrinologists And American College of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(4):479–497. doi:10.4158/EP171764.GL28156151
   PubMed Web of Science ®Google Scholar
• Chinese Medical Association Cardiovascular Diseases Committee, Chinese Gerontology Society Cardiovascular and Cerebrovascular Diseases Committee. Clinical experts on selective cholesterol absorption inhibitors (2013 Edition). Chin J Intern Med. 2013;52:617–620.
   Google Scholar
• ZhaoS, WangY, MuY, et al. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS). Atherosclerosis. 2014;235(2):463–469. doi:10.1016/j.atherosclerosis.2014.05.91624950001
   PubMed Web of Science ®Google Scholar
• WangF, YeP, HuD, et al. Lipid-lowering therapy and lipid goal attainment in patients with metabolic syndrome in China: subgroup analysis of the Dyslipidemia International Study-China (DYSIS-China). Atherosclerosis. 2014;64(16):C109–C110.
   Google Scholar
• HouQ, YuC, LiS, et al. Characteristics of lipid profiles and lipid control in patients with diabetes in a tertiary hospital in Southwest China: an observational study based on electronic medical records. Lipids Health Dis. 2019;18(1):13. doi:10.1186/s12944-018-0945-830636643
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ CTT Collaborator. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statin. Lancet. 2005;366(9493):1267–1278. doi:10.1016/S0140-6736(05)67394-116214597
   PubMed Web of Science ®Google Scholar
• BaysH, DujovneC. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin Pharmacother. 2003;4:779–790.12740000
   PubMed Web of Science ®Google Scholar
• HPS THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279–1291. doi:10.1093/eurheartj/eht05523444397
   PubMed Web of Science ®Google Scholar
• ArmitageJ, BowmanL, WallendszusK, et al.; for Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010;376(9753):1658–1669.21067805
   PubMed Web of Science ®Google Scholar
• CannonCP, BlazingMA, GiuglianoRP. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397. doi:10.1056/NEJMoa141048926039521
   PubMed Web of Science ®Google Scholar
• ClarkeAT, JohnsonPCD, HallGC, et al. High dose atorvastatin associated with increased risk of significant hepatotoxicity in comparison to simvastatin in UK GPRD cohort. PLoS One. 2016;11(3):e0151587. doi:10.1371/journal.pone.015158726983033
   PubMed Web of Science ®Google Scholar
• RanD, NieHJ, GaoYL, et al. A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): ezetimibe and rosuvastatin versus high-dose rosuvastatin. Int J Cardiol. 2017;235(Complete):49–55. doi:10.1016/j.ijcard.2017.02.09928291622
   PubMed Web of Science ®Google Scholar
• Chinese Pharmacoeconomics. China guidelines for pharmacoeconomic evaluations and manual. J Pharm Econ (2013 Ed). 2013.
   Google Scholar
• Bureau of Statistics of China. China Statistical Yearbook 2018 Available from: http://www.stats.gov.cn/tjsj/ndsj/2018/indexeh.htm. Accessed 8 1 2020.
   Google Scholar
• LiewD, ParkHJ, KoSK. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea. Clin Ther. 2009;31(10):2189–2203. doi:10.1016/j.clinthera.2009.10.01519922890
   PubMed Web of Science ®Google Scholar
• StevanovicJ, PehlivanoglouP, PostmaMJ. Meta-analysis of preference-based quality of life values in heart failure. PLoS One. 2016;11(3):e0152030. doi:10.1371/journal.pone.015203027011260
   PubMed Web of Science ®Google Scholar
• McconnachieA, WalkerA, RobertsonM, et al. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. Eur Heart J. 2014;35(5):290–298. doi:10.1093/eurheartj/eht23223839541
   PubMed Web of Science ®Google Scholar
• AraR, PandorA, TumurI, et al. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries. Clin Ther. 2008;30(8):0–1523.
   Web of Science ®Google Scholar
• CatapanoAL, GrahamI, De BackerG, et al. ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;2016(37):2999–3058. doi:10.1093/eurheartj/ehw272
   Web of Science ®Google Scholar
• DuH, LiX, SuN, et al. Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis. Heart. 2019;105(15):1149–1159. doi:10.1136/heartjnl-2019-314763
   Web of Science ®Google Scholar
• KaziDS, PenkoJ, CoxsonPG, et al. Cost-effectiveness of alirocumab: a just-in-time analysis based on the ODYSSEY outcomes trial. Ann Intern Med 2019;170(4):221–229. doi:10.7326/M18-1776
   Google Scholar
• RossJS, FrazeeSG, GaravagliaSB, et al. Trends in use of ezetimibe after the ENHANCE trial, 2007 through 2010. JAMA Intern Med. 2014;174(9):1486. doi:10.1001/jamainternmed.2014.340425070672
   PubMed Web of Science ®Google Scholar
• LuL, KrumholzHM, TuJV, et al. Impact of the ENHANCE Trial on the use of ezetimibe in the United States and Canada. Am Heart J. 2014;167(5):683–689. doi:10.1016/j.ahj.2014.01.01424766978
   PubMed Web of Science ®Google Scholar
• LuL, KrumholzHM, TuJV, et al. Impact of drug policy on regional trends in ezetimibe use. Circ Cardiovasc Qual Outcomes. 2014;7(4):589. doi:10.1161/CIRCOUTCOMES.114.00102324895451
   PubMed Web of Science ®Google Scholar
• BettersJL. Transporters as drug targets: discovery and development of NPC1L1 inhibitors. Clin Pharmacol Ther. 2010;87(6):117–121. doi:10.1038/clpt.2009.20919907422
   PubMed Web of Science ®Google Scholar
• ThompsonPD, PanzaG, ZaleskiA, et al. Statin-associated side effects. J Am Coll Cardiol. 2016;67(20):2395–2410. doi:10.1016/j.jacc.2016.02.07127199064
   PubMed Web of Science ®Google Scholar
• GrahamJH, SanchezRJ, SaseenJJ, et al. Clinical and economic consequences of statin intolerance in the United States: results from an integrated health system. J Clin Lipidol. 2017;11(1):70. doi:10.1016/j.jacl.2016.10.00328391913
   PubMed Web of Science ®Google Scholar
• SaxonDR, EckelRH. Statin intolerance: a literature review and management strategies. Prog Cardiovasc Dis. 2016;59(2):153–164. doi:10.1016/j.pcad.2016.07.00927497504
   PubMed Web of Science ®Google Scholar
• BaysH, CohenDE, ChalasaniN, et al. An assessment by the statin liver safety task force: 2014 update. J Clin Lipidol. 2014;8(3):S47–S57. doi:10.1016/j.jacl.2014.02.01124793441
   PubMed Web of Science ®Google Scholar
• GrahamDJ. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292(21):2585. doi:10.1001/jama.292.21.258515572716
   PubMed Web of Science ®Google Scholar
• de Labry LimaAO, BallesterVG, SánchezJF, et al. Cost-effectiveness and budget impact of treatment with evolocumab versus statins and ezetimibe for hypercholesterolemia in Spain. Rev Esp Cardiol (Engl Ed) 2018;71(12):1027–1035. doi:10.1016/j.rec.2018.05.003
   Google Scholar
• KormanM, WisløffT. Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting. Eur Heart J Cardiovasc Pharmacother. 2018;4:15–22. doi:10.1093/ehjcvp/pvx01028444187
   PubMed Web of Science ®Google Scholar
• AlmalkiZS, GuoJJ, AlahmariA, et al. Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in patients with a history of acute coronary syndrome: analysis of results of the IMPROVE-IT trial. Heart Lung Circ. 2018;27:656–665. doi:10.1016/j.hlc.2017.05.13928716519
   PubMed Web of Science ®Google Scholar
• DaviesGM, VyasA, BaxterCA. Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States. J Med Econ. 2017;1–20.
   Web of Science ®Google Scholar
• LairesPA, EjzykowiczF, HsuTY, et al. Cost–effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal. J Med Econ. 2015;18(8):1–8. doi:10.3111/13696998.2015.103179425271379
   PubMed Web of Science ®Google Scholar
• RecklessJ, DaviesG, TunceliK, et al. Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study. Value Health. 2010;13(6):726–734. doi:10.1111/j.1524-4733.2010.00742.x20561328
   PubMed Web of Science ®Google Scholar
• MihaylovaB, SchlackowI, HerringtonW, et al. Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: results of the study of heart and renal protection (SHARP). Am J Kidney Dis. 2016;67(4):576–584. doi:10.1053/j.ajkd.2015.09.02026597925
   PubMed Web of Science ®Google Scholar
• NootenFV, DaviesGM, JukemaJW, et al. Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia. Neth Heart J. 2011;19(2):59–60. doi:10.1007/s12471-011-0078-421461034
   PubMed Web of Science ®Google Scholar
• AraR, PandorA, TumurI, et al. Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model. Am J Cardiovasc Drugs. 2008;8(6):419–427. doi:10.2165/0129784-200808060-0000519159125
   PubMed Web of Science ®Google Scholar